10-Q · May 12, 2026
PMV Pharmaceuticals reported a net loss of $18 million for Q1 2026, worsening slightly from a loss of $17.4 million in Q1 2025. The company continues to invest heavily in the rezatapopt clinical program, with $15.33…
Earnings analysis · 10-Q
PMVP earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q does not include the income statement, cash-flow statement, balance sheet detail, or segment disclosures needed to assess quarterly revenue, margins, EPS, operating cash flow, or free cash flow. The…
Read full summary
The extracted 10-Q does not include the income statement, cash-flow statement, balance sheet detail, or segment disclosures needed to assess quarterly revenue, margins, EPS, operating cash flow, or free cash flow. The filing reports $79.4 million of cash, cash equivalents, and marketable securities as of June 30, 2026, but introduces a high-severity going-concern disclosure stating that current resources may not fund planned operations for at least one year. No quantitative revenue or EPS guidance was provided.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
$79.4M in cash and securities
Cash, cash equivalents, and marketable securities totaled $79.4 million as of June 30, 2026. Management stated that interest-rate exposure was not material because of the nature and amount of the company’s money-market funds and marketable securities.
-
Controls remained effective
Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026, with no material changes in internal control over financial reporting during the quarter.
What to watch
-
Going-concern uncertainty
The company disclosed substantial doubt about its ability to continue as a going concern. Management stated that present capital resources may not be sufficient to fund planned operations for at least one year from the August 14, 2026 report date, creating dependence on additional financing.
Management's outlook
No quantitative revenue or EPS outlook was provided in the extracted 10-Q. The filing instead states that present capital resources may not be sufficient to fund planned operations for at least one year from the report date.
Earlier filings 4
10-K · March 6, 2026
PMV Pharmaceuticals continues to pursue clinical development in the competitive biotechnology market with a focus on the lead product candidate rezatapopt. Despite incurring significant net losses and reporting zero…
10-Q · November 12, 2025
PMV Pharmaceuticals reported a net loss of $21.1 million for Q3 2025, consistent with previous quarters of negative performance, resulting in diluted EPS of -$0.4. Total cash and cash equivalents decreased to $36.3…
10-Q · August 7, 2025
PMV Pharmaceuticals, Inc. reported a continued negative performance in Q2 2025, with an operating loss of $22.9 million and a net loss of $21.2 million. The company's revenue remains at $0, reflecting ongoing challenges…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.